Aflibercept Plus FOLFIRI vs. Placebo Plus FOLFIRI in Second-Line Metastatic Colorectal Cancer: a Post Hoc Analysis of Survival from the Phase III VELOUR Study Subsequent to Exclusion of Patients who had Recurrence During or Within 6 Months of Completing Adjuvant Oxaliplatin-Based Therapy
| Autor: | Van Cutsem E, Joulain F, Pm, Hoff, Mitchell E, Ruff P, Lakomý R, Prausová J, Vm, Moiseyenko, van Hazel G, David Cunningham, Arnold D, Hj, Schmoll, Aj, Ten Tije, McKendrick J, Kröning H, Humblet Y, Grávalos C, Le-Guennec S, Andria M, Dochy E |
|---|---|
| Zdroj: | Europe PubMed Central |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|